| Description | Bifikafusp alfa (L19-IL2) is an immunotherapeutic fusion protein that combines human L19 antibodies with the cytokine interleukin 2 (IL2), targeting the extra domain B (EDB) of fibronectin with demonstrated anticancer activity [1]. |
| In vivo | Bifikafusp alfa（每日1.43及4.29 MIU/kg；腹腔内注射；连续10天；雌性NMRI裸鼠MiaPaca-A2异种移植模型）对既有胰腺癌显示出明显的抗肿瘤作用[1]。 |
| Synonyms | L19-IL2 |
| molecular weight | N/A |
| CAS | 1957239-90-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years | Shipping with blue ice. |